264 related articles for article (PubMed ID: 26202532)
1. Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.
Ali-Hasan-Al-Saegh S; Mirhosseini SJ; Shahidzadeh A; Rahimizadeh E; Sarrafan-Chaharsoughi Z; Ghodratipour Z; Lotfaliani M; Rezaeisadrabadi M; Dehghan HR; Bireta C; Weymann A; Sabashnikov A; Popov AF
Kardiol Pol; 2016; 74(2):104-18. PubMed ID: 26202532
[TBL] [Abstract][Full Text] [Related]
2. A comparison of intracoronary with intravenous glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials.
Fu G; Jia L; Zhao X; Wang Y; Chen X; Yang Y; Lu N; Zhao W; Hui R; Zheng Y
J Interv Cardiol; 2012 Jun; 25(3):223-34. PubMed ID: 22413751
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analysis of Randomized Trials of Intracoronary Versus Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Elbadawi A; Elgendy IY; Megaly M; Ha LD; Mahmoud K; Alotaki E; Ogunbayo GO; Baig B; Abuzaid AS; Saad M; Depta JP
Am J Cardiol; 2017 Oct; 120(7):1055-1061. PubMed ID: 28826897
[TBL] [Abstract][Full Text] [Related]
4. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 1-year Major Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention Receiving Intracoronary Bolus Only Versus Intracoronary Bolus Plus Infusion of Glycoprotein IIb/IIIa Inhibitors.
Kassaian SE; Fathi Y; Lotfi-Tokaldany M; Salarifar M; Alidoosti M; Haji-Zeinali AM; Aghajani H; Amirzadegan A; Nozari Y; Mortazavi SH; Jalali A; Saroukhani S
Crit Pathw Cardiol; 2016 Sep; 15(3):89-94. PubMed ID: 27465002
[TBL] [Abstract][Full Text] [Related]
6. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials.
Sun B; Liu Z; Yin H; Wang T; Chen T; Yang S; Jiang Z
Medicine (Baltimore); 2017 Oct; 96(40):e8223. PubMed ID: 28984776
[TBL] [Abstract][Full Text] [Related]
7. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
[TBL] [Abstract][Full Text] [Related]
8. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Friedland S; Eisenberg MJ; Shimony A
Am J Cardiol; 2011 Nov; 108(9):1244-51. PubMed ID: 22000626
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
Xu Q; Yin J; Si LY
Int J Cardiol; 2013 Jan; 162(3):210-9. PubMed ID: 22769575
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
14. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function.
Pellicori P; Torromeo C; Barillà F; Mangieri E; Evangelista A; Truscelli G; Costanzo P; Hoye A; Wong K
Cardiol J; 2013; 20(3):310-7. PubMed ID: 23788306
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction.
Wang Y; Wu B; Shu X
Am J Cardiol; 2012 Apr; 109(8):1124-30. PubMed ID: 22245413
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Tang X; Li R; Jing Q; Liu Y; Liu P
PLoS One; 2015; 10(6):e0129718. PubMed ID: 26067296
[TBL] [Abstract][Full Text] [Related]
17. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Bosch X; Marrugat J; Sanchis J
Cochrane Database Syst Rev; 2013 Nov; (11):CD002130. PubMed ID: 24203004
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Bosch X; Marrugat J; Sanchis J
Cochrane Database Syst Rev; 2013 Oct; (10):CD002130. PubMed ID: 24136036
[TBL] [Abstract][Full Text] [Related]
19. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Bosch X; Marrugat J
Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction.
Esfandi A; Fotouhi M; Allami A; Ebrahimi M
J Atheroscler Thromb; 2016; 23(4):465-76. PubMed ID: 26632161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
